RGC - Regencell Bioscience Holdings Ltd

28.1
-0.570   -2.028%

Share volume: 77,288
Last Updated: 04-20-2026
Pharmaceutical Products/Medicinal Chemicals: -0.15%

PREVIOUS CLOSE
CHG
CHG%
$28.67
-0.57
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
93%
Profitability 100%
Dept financing 50%
Liquidity 75%
Performance 100%
Performance
5 Days
-8.08%
1 Month
11.44%
3 Months
28.25%
6 Months
75.30%
1 Year
-3.10%
2 Year
336.34%
Key data
Stock price
$28.10
P/E Ratio 
0.00
DAY RANGE
$27.73 - $29.18
EPS 
N/A
52 WEEK RANGE
$9.39 - $950.00
52 WEEK CHANGE
-$2.43
MARKET CAP 
94.083 M
YIELD 
N/A
SHARES OUTSTANDING 
13.013 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10-24-2025
BETA 
-5.87
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$107,276
AVERAGE 30 VOLUME 
$171,469
Company detail
CEO: Yat-Gai Au
Region: US
Website: regencellbioscience.com
Employees: 10
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Medicinal Chemicals
Sector: Manufacturing

Regencell Bioscience Holdings Limited focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Recent news